Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare,suggests a new research.
If the cancer is found only in the breast and has not spread to other parts of the body, 99 percent of the people who receive such a diagnosis go on to live cancer-free lives for a minimum of 5 years, according to a study published in JAMA Oncology.
Overall, survival for women who stuck with the low-fat regimen was 22 percent higher compared to women who continued with their usual diet, the researchers noted.
The study has “found yet another health benefit to eating a low-fat diet, and more fruits and vegetables,” said lead researcher Dr Rowan Chlebowski, a research professor at City of Hope Hospital in Duarte, Calif.
“Our study demonstrates that postmenopausal women on a low-fat diet who were diagnosed with breast cancer lived longer,” said Chlebowski, who works at the hospital’s department of medical oncology and therapeutics research.
As his team noted, data from the Women’s Health Initiative (WHI) study had already found that women who ate a low-fat diet were at lower odds of developing more aggressive forms of breast cancer.
For the study, Chlebowski’s group looked at WHI data on nearly 49,000 postmenopausal women tracked by 40 clinical centers across the United States.
The women were randomly selected to stick with their regular diet (a third or more of daily energy supplied by fat) or to adopt a regimen with more fruits, vegetables and whole grains, where less than 20 percent of daily energy needs came from fat.
Over the 8.5 years of the diet study, 1,764 of the women developed breast cancer. Outcomes for these women were tracked for an average of 11.5 years after their diagnosis.
Looking at death from breast cancer specifically, of the 516 women who died from any cause, 68 in the low-fat diet group died of breast cancer, compared to 120 in the regular-diet group, the researchers said.
Women who ate less dietary fat were also less likely to have died of other causes, especially heart disease. While 64 women who ate fattier diets died of heart disease over the study period, that number fell to just 27 for women in the low-fat diet group, the findings showed.
The take-home message, according to Chlebowski: “Following a low-fat diet — at any point in your life — can have tremendous health benefits.”
With Agency InputsFollow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost